 |
市场调查报告书
商品编码
1391890
整合酶抑制剂市场：按药物、途径、配销通路和地区Integrase Inhibitors Market, By Drug (Raltegravir, Dolutegravir, Elvitegravir, Bictegravir, and Others ), By Route of Administration, By Distribution Channel, By Geography |
||||||
2023年全球整合酶抑制剂市场规模为147亿美元，预计2030年将达217亿美元，2023年至2030年年复合成长率（CAGR）为5.7%。据预测。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2022年 | 2023年市场规模 | 147亿美元 |
| 实绩资料 | 2018-2021 | 预测期 | 2023-2030 |
| 预测期CAGR | 5.70% | 2030年市场规模预测 | 217亿美元 |
整合酶抑制剂是一类相对较新的抗逆转录病毒药物，用于治疗爱滋病毒/爱滋病。 HIV整合酶抑制剂透过特异性抑制HIV整合酶发挥作用，HIV整合酶是一种逆转录病毒酶，对于宿主细胞内HIV基因组的复製至关重要。整合酶抑制剂可阻止 HIV 病毒 DNA 整合到受感染细胞的染色体 DNA 中，并防止新的 HIV 病毒粒子繁殖。 Raltegravir是第一代整合酶抑制剂，于2007年核准，提供了抑制HIV复製的新作用机制。在临床试验中显示出高疗效和良好的耐受性。此后，新一代整合酶抑制剂，如埃替拉韦、多替拉韦等相继被开发出来并核准。这些药物比现有的抗爱滋病毒疗法具有更好的疗效和耐受性。整合酶抑制剂的引入大大扩展了爱滋病毒管理的治疗选择。整合酶抑制剂透过阻断病毒 DNA 整合到宿主细胞 DNA 中来治疗 HIV/爱滋病，主要是透过抑制称为整合酶的病毒酶的活性。
市场动态：
全球整合酶抑制剂市场的成长主要由全球爱滋病毒/爱滋病疾病负担的增加、爱滋病毒抗逆转滤病毒治疗（ART）的日益普及以及新的和改进的整合酶抑制剂产品平臺的推出推动。 。 HIV/爱滋病盛行率的增加、药物开发的进步、整合酶抑制剂的功效和安全性是预计在预测期内推动全球整合酶抑制剂市场成长的主要因素。已开发国家有关抗逆转录病毒治疗应用的有利政府倡议提供了有利可图的机会。然而，HIV抗药性菌株的出现以及整合酶抑制剂治疗的高成本可能会对市场成长产生负面影响。市场主要企业致力于长效注射/口服製剂的研究和开发，以提高治疗医嘱遵从性并增加商机。
本研究的主要特点
- 该报告详细分析了全球整合酶抑制剂市场，并提供了以2022年为基准年的预测期（2023-2030）的市场规模和年复合成长率（CAGR %）。
- 它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
- 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
- 它根据以下参数（例如公司亮点、产品系列、主要亮点、财务实绩和策略）介绍了全球整合酶抑制剂市场的主要企业。
- 该报告的见解使行销人员和经营团队负责人就未来的产品发布、类型升级、市场扩张和行销策略做出资讯的决策。
- 全球整合酶抑制剂市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
- 透过用于分析全球整合酶抑制剂市场的各种策略矩阵，将有助于相关人员做出决策。
目录：
第1章调查目的和假设
- 研究目标
- 假设
- 简称
第2章市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map（COM）
第3章市场动态、法规及趋势分析
- 市场动态
- 爱滋病毒/爱滋病盛行率上升，药物开发、功效和安全性取得进展
- 高治疗成本、副作用与安全问题
- 具有改善治疗效果的整合酶抑制剂
- 影响分析
- 主要亮点
- 监管场景
- 产品发布/核准
- PEST分析
- 波特的分析
- 併购场景
第4章全球整合酶抑制剂市场 -冠状病毒（COVID-19）大流行的影响
- 新型冠状病毒感染疾病（COVID-19）的流行病学
- 供需面分析
- 经济影响
第5章全球整合酶抑制剂市场（按药物），2018-2030
- 介绍
- 拉替拉韦
- 多替拉韦
- 埃维特拉韦
- 比克替拉韦
- 其他（卡博替拉韦等）
第6章全球整合酶抑制剂市场，依给药途径，2023-2030
- 介绍
- 口服
- 静脉
- 其他的
第7章全球整合酶抑制剂市场，依配销通路划分，2023-2030 年
- 介绍
- 医院药房
- 零售药房
- 线上药房
第8章全球整合酶抑制剂市场，按地区，2023-2030
- 介绍
- 北美洲
- 美国
- 加拿大
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 欧洲其他地区
- 亚太地区
- 印度
- 中国
- 日本
- 澳洲
- 东南亚国协
- 韩国
- 其他亚太地区
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 中东
- 海湾合作委员会国家
- 以色列
- 其他中东地区
- 非洲
- 北非
- 中部非洲
- 南非
第9章竞争形势
- Gilead Sciences
- ViiV Healthcare group
- Merck & Co., Inc
- GlaxoSmithKline PLC
- Bristol-Myers Squibb Company
- Johnson & Johnson
- AbbVie Inc
- Janssen Pharmaceuticals, Inc
- Theratechnologies Inc
- Shionogi & Co., Ltd
- Viatris Inc.
第10章章
- 调查方法
- 关于出版商
The global integrase inhibitors market size was valued at US$ 14.7 billion in 2023 and is expected US$ 21.7 billion by 2030 is expected to grow at a compound annual growth rate (CAGR) of 5.7% from 2023 to 2030.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 14.7 Bn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 5.70% | 2030 Value Projection: | US$ 21.7 Bn |
Integrase inhibitors are a relatively new class of antiretroviral drugs used for the treatment of HIV/AIDS. They work by specifically inhibiting HIV integrase, a retroviral enzyme that is essential for the replication of HIV's genome in host cells. Integrase inhibitors prevent integration of HIV viral DNA into the chromosomal DNA of the infected cells, thus blocking the propagation of new HIV virions. The first generation integrase inhibitor raltegravir was approved in 2007, offering a novel mechanism of action in suppressing HIV replication. It demonstrated high efficacy and good tolerability in clinical trials. Since then, newer generations of integrase inhibitors like elvitegravir and dolutegravir have been developed and approved. These agents have shown improved effectiveness and tolerability profiles over existing anti-HIV therapies. The introduction of integrase inhibitors has significantly expanded treatment options for HIV management. Integrase Inhibitors are primarily used in the treatment of HIV/AIDS by inhibiting the activity of the viral enzyme called integrase, thereby preventing the integration of the viral DNA into the host cell's DNA.
Market Dynamics:
The global integrase inhibitors market growth is primarily driven by the rising HIV/AIDS disease burden worldwide, increasing adoption of antiretroviral treatment (ART) for HIV, and robust product pipeline with introduction of newer and improved integrase inhibitor drugs. Increasing prevalence of HIV/AIDS, advancements in drug development, efficacy and safety of integrase inhibitors are major factors expected to drive growth of the global integrase inhibitors market during the forecast period. Favorable government initiatives in developed nations regarding coverage of antiretroviral therapy presents lucrative opportunities. However, the market growth can be negatively impacted by the emergence of drug-resistant strains of HIV and high costs of integrase inhibitor therapies. Key market players are engaged in R&D of long-acting injectable/oral formulations to increase adherence to treatment and drive revenue opportunities.
Key features of the study:
- This report provides in-depth analysis of the global integrase inhibitors market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global integrase inhibitors market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Gilead Sciences, ViiV Healthcare group, Merck & Co., Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Janssen Pharmaceuticals, Inc., Theratechnologies Inc., Shionogi & Co., Ltd., and Viatris Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global integrase inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global integrase inhibitors market.
Detailed Segmentation:
- By Drug:
- Raltegravir
- Dolutegravir
- Elvitegravir
- Bictegravir
- Others (Cabotegravir, etc.)
- By Route of Administration:
- Oral
- Intravenous
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Gilead Sciences
- ViiV Healthcare group
- Merck & Co., Inc.
- GlaxoSmithKline PLC
- Bristol-Myers Squibb Company
- Johnson & Johnson
- AbbVie Inc.
- Janssen Pharmaceuticals, Inc.
- Theratechnologies Inc.
- Shionogi & Co., Ltd.
- Viatris Inc.
Table of Contents:
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Integrase Inhibitor, By Drug
- Market Integrase Inhibitor, By Route of Administration
- Market Integrase Inhibitor, By Distribution Channel
- Market Integrase Inhibitor, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing prevalence of HIV/AIDS, advancements in drug development, efficacy and safety
- High Treatment Costs, Side Effects and Safety Concerns
- Integrase Inhibitors with improved therapeutic profiles.
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Integrase Inhibitors Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Integrase Inhibitors Market, By Drug, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Raltegravir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Dolutegravir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Elvitegravir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Bictegravir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Others (Cabotegravir, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
6. Global Integrase Inhibitors Market, By Route of Administration, 2023-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
7. Global Integrase Inhibitors Market, By Distribution Channel, 2023-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
8. Global Integrase Inhibitors Market, By Region, 2023-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Bn)
- India
- China
- Japan
- Australia
- ASEAN
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018 - 2030, (US$ Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- ViiV Healthcare group
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Janssen Pharmaceuticals, Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Theratechnologies Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Shionogi & Co., Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Analyst Views
10. Section
- Research Methodology
- About us
